Jing Zhang1, Rongrong Zhang2, Zhenhong Zhao3. 1. Endocrine Department, Guangrao County People's Hospital Dongying, Shandong, China. 2. Department of Nuclear Medicine, Dongping Hospital Affiliated to Shandong First Medical University Shandong, China. 3. Department of Emergency Medicine, Qingdao 8th People's Hospital Shandong, China.
Abstract
OBJECTIVE: To study the changes of autoantibodies and intercellular adhesion molecule-1 (ICAM-1) in patients with Graves disease (GD) after clinical treatment. METHODS: A total of 68 patients with GD admitted to our hospital from August 2018 to August 2019 were selected as the research objects. The thyroid peroxidase antibody (TPOAb), thyroid stimulating antibody (TSAb), and antithyroglobulin antibody (TgAb), ICAM-1, insulin-like growth factor 1 (IGF-1), Interleukin-6 (IL-6), Interleukin 17 (IL-17) before and after treatment were examined. RESULTS: The levels of TSAb, TgAb and TPOAb after treatment were remarkably lower than those before treatment (P<0.001); the levels of ICAM-1, IGF-1, IL-17 and IL-6 after treatment were noticeably lower than those before treatment (P<0.001); the FT3 and FT4 levels of patients after treatment were significantly lower than those before treatment (P<0.001), and the FSH level was significantly higher than that before treatment (P<0.001). CONCLUSION: Clinical treatment can remarkably reduce the levels of autoantibodies, ICAM-1 and IGF-1 in GD patients, improve thyroid function, and relieve inflammation. The detection of the above indicators can provide guidance for the progression and treatment of GD. AJTR
OBJECTIVE: To study the changes of autoantibodies and intercellular adhesion molecule-1 (ICAM-1) in patients with Graves disease (GD) after clinical treatment. METHODS: A total of 68 patients with GD admitted to our hospital from August 2018 to August 2019 were selected as the research objects. The thyroid peroxidase antibody (TPOAb), thyroid stimulating antibody (TSAb), and antithyroglobulin antibody (TgAb), ICAM-1, insulin-like growth factor 1 (IGF-1), Interleukin-6 (IL-6), Interleukin 17 (IL-17) before and after treatment were examined. RESULTS: The levels of TSAb, TgAb and TPOAb after treatment were remarkably lower than those before treatment (P<0.001); the levels of ICAM-1, IGF-1, IL-17 and IL-6 after treatment were noticeably lower than those before treatment (P<0.001); the FT3 and FT4 levels of patients after treatment were significantly lower than those before treatment (P<0.001), and the FSH level was significantly higher than that before treatment (P<0.001). CONCLUSION: Clinical treatment can remarkably reduce the levels of autoantibodies, ICAM-1 and IGF-1 in GDpatients, improve thyroid function, and relieve inflammation. The detection of the above indicators can provide guidance for the progression and treatment of GD. AJTR
Authors: Laura C Lane; Kathleen R Allinson; Katy Campbell; Ishita Bhatnagar; Lorna Ingoe; Salman Razvi; Tim Cheetham; Heather J Cordell; Simon H Pearce; Anna L Mitchell Journal: Clin Endocrinol (Oxf) Date: 2018-11-05 Impact factor: 3.478
Authors: Sophia Missoury; Stéphane Plancqueel; Ines Li de la Sierra-Gallay; Wenhua Zhang; Dominique Liger; Dominique Durand; Raoudha Dammak; Bruno Collinet; Herman van Tilbeurgh Journal: Nucleic Acids Res Date: 2018-06-20 Impact factor: 16.971